Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: A naturalistic study

Journal of Clinical Psychiatry

Volumn 68, Issue 10, 2007, Pages 1552-1556

  Tundo, Antonio ^a,b   Salvati, Loretta ^a   Busto, Gianluca ^a   Di Spigno, Daniela ^a   Falcini, Roberta ^a  

^a Institute of Psychopathology   (Italy)

^b Istituto di Psicopatologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAZODONE; TRYPTOPHAN; VALPROIC ACID; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EATING DISORDER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 35948983357     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1013     Document Type: Article

References (27)

1. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl 1998;64-70
2. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-106
3. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and Citalopram in the treatment of obsessive-compulsive disorder: a single blind study. J Clin Psychopharmacol 1997;17:267-271
4. Abramowitz JS. Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Behav Ther 1996;27:583-600
5. Franklin ME, Foa EB. Cognitive-behavioral treatments for obsessive-compulsive disorder. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998:367-386
6. Ballanger JC. Current treatment of anxiety disorders in adults.Biol Psychiatry 1999;46:1579-1594
7. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52
8. Pigott TA, Seay S. Biological treatments for obsessive-compulsive disorder: literature review. In: Swinson RP, Antony MM, Rachman S, et al, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Publications;1998:298-326
9. Kozak MU, Liebowitz ML, Foa EB. Cognitive behavior therapy and pharmacotherapy for OCD. In: Goodman WK, Rudorfer M, Maser JD, eds. Obsessive-Compulsive Disorder. Mahwah, NJ: Lawrence Erlbaum Associates; 2000:501-523
10. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive-compulsive disorder. J Clin Psychiatry 1993;54(suppl):4-9
11. Perse T. Obsessive-compulsive disorder: a treatment review. J Clin Psychiatry 1988;49:48-55
12. Greist JH. Behavior therapy for obsessive compulsive disorder. J Clin Psychiatry 1994;55(suppl):60-68
13. Foa EB, Grayson JB, Steketee GS, et al. Success and failure in the behavioral treatment of obsessive-compulsive disorder. J Consult Clin Psychol 1983;51:287-297
14. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology 1998;136:205-216
15. Lucey JV, Butcher G, Clare AW, et al. The clinical characteristics of patients with obsessive-compulsive disorders: a descriptive study of an Irish sample. Int J Psychol Med 1994;11:11-14
16. March JS, Frances A, Carpenter D, et al. The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):3-72
17. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999;60:584-590
18. Kampman M, Keijsers GPG, Hoogduin CAL, et al. Addiction of cognitive-behavior therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand 2002;106:314-319
19. Tolin DF, Maltby N, Diefenbach GJ, et al. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry 2004;65:922-931
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
21. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
22. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: validity. Arch Gen Psychiatry 1989;46:1012-1016
23. Koran LM, Saxena S. Issues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectr 2000;5(suppl 4):24-31
24. Kozak MJ, Foa EB. Mastery of Obsessive-Compulsive Disorder: a Cognitive-Behavioral Approach. San Antonio, Tex: The Psychological Corporation; 1997
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
26. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-659
27. Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003;71:394-398